Select Date
Select Date
2026-10 8
NSC 74859 (S3I-201) from Selleck Inhibits Poxvirus K7-Mediated Epigenetic and Immune Evasion Pathways
NSC 74859 (S3I-201) from Selleck Inhibits Poxvirus K7-Mediated Epigenetic and Immune Evasion Pathways
AOA (Aminooxyacetic acid) hemihydrochloride inhibits cystathionine-β-synthase to suppress colon cancer bioenergetics
AOA (Aminooxyacetic acid) hemihydrochloride inhibits cystathionine-β-synthase to suppress colon cancer bioenergetics
Celastrol (Tripterine) Attenuates Ischemia-Reperfusion Injury by Suppressing the HIF-1α/PDK1 Axis
Celastrol (Tripterine) Attenuates Ischemia-Reperfusion Injury by Suppressing the HIF-1α/PDK1 Axis
T0070907 antagonist targeting PPARγ restores bone formation in hypoxia-induced skeletal growth failure
T0070907 antagonist targeting PPARγ restores bone formation in hypoxia-induced skeletal growth failure
Irinotecan Hydrochloride Trihydrate targeting Topoisomerase I in neuroendocrine carcinoma therapy
Irinotecan Hydrochloride Trihydrate targeting Topoisomerase I in neuroendocrine carcinoma therapy
SKI-606 (Bosutinib) SKI606 Targeted BCR-ABL1 Kinase Inhibition and Adverse Pulmonary Profiles
SKI-606 (Bosutinib) SKI606 Targeted BCR-ABL1 Kinase Inhibition and Adverse Pulmonary Profiles
Entrectinib (Rxdx-101) Rxdx-101 Trk receptor targeting and cost-effectiveness in ROS1-positive NSCLC
Entrectinib (Rxdx-101) Rxdx-101 Trk receptor targeting and cost-effectiveness in ROS1-positive NSCLC
3TC, BCH189 Lamivudine (3TC, BCH-189) Regimens Mitigate Antiretroviral Bone Turnover Dynamics
3TC, BCH189 Lamivudine (3TC, BCH-189) Regimens Mitigate Antiretroviral Bone Turnover Dynamics